Clinical Trials Browser

INDUSTRY × Interventional × Hepatoblastoma × Clear all

Fibrolamellar hepatocellular carcinoma, Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Melanoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma

NCT04337177 2025-09-23

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Phase 1 Recruiting

20 enrolled

CNSGastrointestinalSarcoma

Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma

NCT04634357 2025-04-09

ARYA-2

Phase 1/2 Recruiting

15 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Hepatoblastoma

NCT02085148 2024-04-22

A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy

Phase 1 Completed

62 enrolled

CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma

NCT01125800 2017-03-20

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Phase 1/2 Completed

76 enrolled 18 charts

CNSGastrointestinalSarcoma

Astrocytoma, Glioma, Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Hepatoblastoma

Clinical Trials

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

ARYA-2

A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB